TY - JOUR
T1 - Costing Dengue Fever Cases and Outbreaks
T2 - Recommendations from a Costing Dengue Working Group in the Americas
AU - Constenla, Dagna
AU - Armien, Blas
AU - Arredondo, Juan
AU - Carabali, Maribel
AU - Carrasquilla, Gabriel
AU - Castro, Raul
AU - Durand, Laure
AU - Durán-Arenas, Luis
AU - García, Maria Elena
AU - Gallegos, Rivera Verónica
AU - Gontes, Maria Luisa
AU - López, Juan Guillermo
AU - McFarlane, Charlton
AU - Montoya, Romeo
AU - Sartori, Ana Maria
AU - Siqueira, João Bosco
AU - Martelli, Celina Turchi
N1 - Funding Information:
Source of financial support: These dengue costing guidelines are the result of a sponsored grant from the Pan American Health Education Foundation (PAHEF) that was primarily funded by Sanofi Pasteur. Full independence of methods and control over publication remain with the authors, along with responsibility for any errors.
Publisher Copyright:
© 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Objectives: The overall aim of this article was to present a step-by-step guideline for determining the costs associated with dengue in dengue-endemic countries of the Latin American and the Caribbean region and to illustrate how each of these steps can be applied in dengue costing studies. Methods: An expert panel was convened to develop standards for costing dengue so that over the next decade, decision makers will have access to improved information on the true cost of dengue in endemic countries of the Latin American and the Caribbean region. We described the outcome of the expert panel meeting, which resulted in the provision of a step-by-step dengue costing guideline that aims to provide direction to planners and program managers on how to estimate dengue economic burden studies, and provide a discussion forum of the methods used to cost dengue fever cases and outbreaks in a manner that should be accessible to persons with some familiarity with a cost study. Results: The guideline includes nine sequential steps: 1) definition of the scope of the study; 2) identification of the target population; 3) description of the study perspective; 4) definition of the time horizon; 5) calculation of the sample size; 6) definition of the unit of analysis; 7) identification of the cost items; 8) measurement and valuation of the cost items; and 9) handling of uncertainty. The trade-off between accurate, patient-level cost estimates and data availability constraints is discussed. Conclusions: The current guideline is the result of constructive collaboration among a multidisciplinary research team to better ascertain the true economic burden of dengue across countries of the region.
AB - Objectives: The overall aim of this article was to present a step-by-step guideline for determining the costs associated with dengue in dengue-endemic countries of the Latin American and the Caribbean region and to illustrate how each of these steps can be applied in dengue costing studies. Methods: An expert panel was convened to develop standards for costing dengue so that over the next decade, decision makers will have access to improved information on the true cost of dengue in endemic countries of the Latin American and the Caribbean region. We described the outcome of the expert panel meeting, which resulted in the provision of a step-by-step dengue costing guideline that aims to provide direction to planners and program managers on how to estimate dengue economic burden studies, and provide a discussion forum of the methods used to cost dengue fever cases and outbreaks in a manner that should be accessible to persons with some familiarity with a cost study. Results: The guideline includes nine sequential steps: 1) definition of the scope of the study; 2) identification of the target population; 3) description of the study perspective; 4) definition of the time horizon; 5) calculation of the sample size; 6) definition of the unit of analysis; 7) identification of the cost items; 8) measurement and valuation of the cost items; and 9) handling of uncertainty. The trade-off between accurate, patient-level cost estimates and data availability constraints is discussed. Conclusions: The current guideline is the result of constructive collaboration among a multidisciplinary research team to better ascertain the true economic burden of dengue across countries of the region.
KW - Costing
KW - Dengue fever cases
KW - Dengue outbreaks
UR - http://www.scopus.com/inward/record.url?scp=84938080024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938080024&partnerID=8YFLogxK
U2 - 10.1016/j.vhri.2015.06.001
DO - 10.1016/j.vhri.2015.06.001
M3 - Article
AN - SCOPUS:84938080024
SN - 2212-1099
VL - 8
SP - 80
EP - 91
JO - Value in Health Regional Issues
JF - Value in Health Regional Issues
ER -